FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980354625> ?p ?o ?g. }

• W2980354625 endingPage "5511" @default.
• W2980354625 startingPage "5511" @default.
• W2980354625 abstract "Abstract Introduction: Erythropoietin stimulating agents (ESAs) are first-line therapy for International Prognostic Scoring System (IPSS)-low risk myelodysplastic syndrome (MDS) when symptomatic anaemia (Hb <10 g/dl) is associated with serum erythropoietin (EPO) <500 mU/mL. Treatment response rate, according to international working group (IWG) response criteria (1- 5), ranges from 40 to 60%. Attempts have been made to build prognostic scores (integrating transfusion need, erythropoietin level, R-IPSS and ferritin) able to predict response to ESAs (6-7). No data concerning the predictive value of morphological and immunohistochemical analysis on bone marrow biopsy in low risk MDS patients are emerged till now. Methods: We retrospectively examined 96 IPSS low/int-1 MDS patients treated with ESAs in order to evaluate the morphological and immunohistochemical features of the bone marrow biopsies performed at baseline. All the patients had hemoglobin (Hb) ≤10 g/dL and serum EPO <500 mU/mL and received EPO alfa or β 40 000-80 000 IU/week for at least 12 weeks. Response to ESAs treatment was evaluated according to IWG 2006 criteria. A detailed analysis of the morphological features (including quantitative and qualitative changes in the erythroid, myeloid and megakariopoyetic lineages) was performed, together with an immunohistochemical evaluation of p53 expression and CD34-positive blasts percentage. Results: Sixty-eight percent of the patients were classified as responder while 32% as non-responder. The morphologic profiles of the responder and non-responder did not differ significantly. A significant correlation was found between the response to the therapy and a percentage of CD34-positive blasts > 3% (univariate analysis: p= .0211). Moreover p53 expression in less than 1% of the nucleated cells correlated with the treatment response (univariate analysis: p = .0086). These results were also confirmed on multivariate analysis (p= .002). Fifty-eight percent of patients maintained response to ESAs for the entire duration of the follow up while 42% lost the response (median follow up: 35 months). More than 3% CD34-positive blasts was associated with a higher probability to lose the response to ESAs (p = .00003). Kaplan-Meier method was than applied to estimate the response duration. Patients with more than 3% CD34-positive blasts showed earlier loss of response in comparison with those with a lower percentage of blasts (p value= .0003; HR=3.9, IC 95% 1.8154-8.6238). Finally, the expression of p53 in more than ≥ 1% of the nucleated cells correlated with the loss of response before 24 mounts (p value= 0.029). Conclusions: Our study identifies 2 well-known parameters that could be useful to better predict outcome of ESAs therapy in low risk MDS patients. Therefore role of bone marrow biopsy together with its diagnostic contribution in the clinical evaluation of MDS patients (cellularity, morphologic dysplasia, percentage of CD34-positive blasts, grading of bone marrow fibrosis) could be helpful as a predictive tool in ESAs candidate patients. Further studies based on larger series of patients are needed to confirm these preliminary results. Disclosures Reda: Gilead: Consultancy; ABBVIE: Consultancy; Janssen and Cilag: Consultancy; Celgene: Consultancy. Riva:Jannsen and Cilag: Consultancy; Novartis: Consultancy; Celgene: Consultancy. Molteni:Janssen and Cilag: Consultancy; Novartis: Consultancy; Italfarmaco: Consultancy; Celgene: Consultancy; AMGEN: Consultancy. Cortelezzi:abbvie: Consultancy; novartis: Consultancy; roche: Consultancy; janssen: Consultancy." @default.
• W2980354625 created "2019-10-25" @default.
• W2980354625 creator A5003225344 @default.
• W2980354625 creator A5013841162 @default.
• W2980354625 creator A5016051239 @default.
• W2980354625 creator A5027648948 @default.
• W2980354625 creator A5032278130 @default.
• W2980354625 creator A5035721133 @default.
• W2980354625 creator A5039731694 @default.
• W2980354625 creator A5054957586 @default.
• W2980354625 creator A5070924011 @default.
• W2980354625 creator A5080135856 @default.
• W2980354625 creator A5088208492 @default.
• W2980354625 date "2018-11-29" @default.
• W2980354625 modified "2023-10-14" @default.
• W2980354625 title "P53 and CD34 Immunohistochemical Expression on Bone Marrow Biopsy As Predictive Marker of Response to Erythropoietin in Low Risk Myelodysplastic Syndrome" @default.
• W2980354625 doi "https://doi.org/10.1182/blood-2018-99-118811" @default.
• W2980354625 hasPublicationYear "2018" @default.
• W2980354625 type Work @default.
• W2980354625 sameAs 2980354625 @default.
• W2980354625 citedByCount "0" @default.
• W2980354625 crossrefType "journal-article" @default.
• W2980354625 hasAuthorship W2980354625A5003225344 @default.
• W2980354625 hasAuthorship W2980354625A5013841162 @default.
• W2980354625 hasAuthorship W2980354625A5016051239 @default.
• W2980354625 hasAuthorship W2980354625A5027648948 @default.
• W2980354625 hasAuthorship W2980354625A5032278130 @default.
• W2980354625 hasAuthorship W2980354625A5035721133 @default.
• W2980354625 hasAuthorship W2980354625A5039731694 @default.
• W2980354625 hasAuthorship W2980354625A5054957586 @default.
• W2980354625 hasAuthorship W2980354625A5070924011 @default.
• W2980354625 hasAuthorship W2980354625A5080135856 @default.
• W2980354625 hasAuthorship W2980354625A5088208492 @default.
• W2980354625 hasBestOaLocation W29803546251 @default.
• W2980354625 hasConcept C10205521 @default.
• W2980354625 hasConcept C126322002 @default.
• W2980354625 hasConcept C142724271 @default.
• W2980354625 hasConcept C143998085 @default.
• W2980354625 hasConcept C204232928 @default.
• W2980354625 hasConcept C2775934546 @default.
• W2980354625 hasConcept C2778248108 @default.
• W2980354625 hasConcept C2778319317 @default.
• W2980354625 hasConcept C2778534260 @default.
• W2980354625 hasConcept C2780007613 @default.
• W2980354625 hasConcept C2780240888 @default.
• W2980354625 hasConcept C2780817109 @default.
• W2980354625 hasConcept C28328180 @default.
• W2980354625 hasConcept C54355233 @default.
• W2980354625 hasConcept C71924100 @default.
• W2980354625 hasConcept C86803240 @default.
• W2980354625 hasConcept C90924648 @default.
• W2980354625 hasConceptScore W2980354625C10205521 @default.
• W2980354625 hasConceptScore W2980354625C126322002 @default.
• W2980354625 hasConceptScore W2980354625C142724271 @default.
• W2980354625 hasConceptScore W2980354625C143998085 @default.
• W2980354625 hasConceptScore W2980354625C204232928 @default.
• W2980354625 hasConceptScore W2980354625C2775934546 @default.
• W2980354625 hasConceptScore W2980354625C2778248108 @default.
• W2980354625 hasConceptScore W2980354625C2778319317 @default.
• W2980354625 hasConceptScore W2980354625C2778534260 @default.
• W2980354625 hasConceptScore W2980354625C2780007613 @default.
• W2980354625 hasConceptScore W2980354625C2780240888 @default.
• W2980354625 hasConceptScore W2980354625C2780817109 @default.
• W2980354625 hasConceptScore W2980354625C28328180 @default.
• W2980354625 hasConceptScore W2980354625C54355233 @default.
• W2980354625 hasConceptScore W2980354625C71924100 @default.
• W2980354625 hasConceptScore W2980354625C86803240 @default.
• W2980354625 hasConceptScore W2980354625C90924648 @default.
• W2980354625 hasIssue "Supplement 1" @default.
• W2980354625 hasLocation W29803546251 @default.
• W2980354625 hasOpenAccess W2980354625 @default.
• W2980354625 hasPrimaryLocation W29803546251 @default.
• W2980354625 hasRelatedWork W1996195106 @default.
• W2980354625 hasRelatedWork W1996281436 @default.
• W2980354625 hasRelatedWork W2084816666 @default.
• W2980354625 hasRelatedWork W2160204079 @default.
• W2980354625 hasRelatedWork W2358040292 @default.
• W2980354625 hasRelatedWork W2362864083 @default.
• W2980354625 hasRelatedWork W2412866400 @default.
• W2980354625 hasRelatedWork W2433294562 @default.
• W2980354625 hasRelatedWork W2548073857 @default.
• W2980354625 hasRelatedWork W2576988132 @default.
• W2980354625 hasVolume "132" @default.
• W2980354625 isParatext "false" @default.
• W2980354625 isRetracted "false" @default.
• W2980354625 magId "2980354625" @default.
• W2980354625 workType "article" @default.